cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma

Amy B. Heimberger*, Shashwat Tripathi, Hinda Najem, Akanksha Sanjay Mahajan, Peng Zhang, Justin T. Low, Alexander H. Stegh, Michael A. Curran, David M. Ashley, Charles David James

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is known to contain immune suppressive myeloid cells with minimal effector T cell infiltration. Stimulator of interferon genes (STING) is an important activator of immune response and results in production of Type 1 interferon and antigen presentation by myeloid cells. This review will discuss important developments in STING agonists, potential biomarkers for STING response, and new combinatorial therapeutic approaches in gliomas.

Original languageEnglish (US)
Article number1010
StatePublished - 2022


  • Glioblastoma
  • Immune cells
  • Immune therapies
  • Myeloid cells
  • STING Agonist
  • T cells
  • Tumor microenvironment

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Immunology and Microbiology
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma'. Together they form a unique fingerprint.

Cite this